Genomeditierung

Lilly’s $1.1B Recombinase Push for Hearing Loss

Eli Lilly has inked an exclusive research and licensing deal with Seamless Therapeutics worth up to $1.12 billion to develop programmable recombinase gene-editing therapies for in… Jan 28, 2026

Genetics

Topical CRISPR Targets Skin Disease

UBC researchers report a topical CRISPR treatment that repairs disease-causing mutations in human skin models using laser-assisted lipid nanoparticles, a potential platform for in… Jan 27, 2026

Genetics

One‑Shot Gene Editor Targets Nonsense Mutations

A new gene‑editing platform called PERT uses engineered suppressor tRNA to bypass premature stop signals in DNA, rescuing protein production in cells and mice and offering a poten… Dez 05, 2025

Genetics

How AI Is Reinventing CRISPR

Researchers are merging machine learning and genome editing to design better nucleases, predict outcomes, and speed experiment planning — but technical, ethical and regulatory hur… Nov 18, 2025

Genomeditierung

Artikel über Genomeditierung

Lilly’s $1.1B Recombinase Push for Hearing Loss

Topical CRISPR Targets Skin Disease

One‑Shot Gene Editor Targets Nonsense Mutations

How AI Is Reinventing CRISPR